View Item 

Show simple item record

Circulating vitamin D, vitamin D–related genetic variation, and risk of fatal prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium

dc.contributor.authorShui, Irene M.en_US
dc.contributor.authorMondul, Alison M.en_US
dc.contributor.authorLindström, Saraen_US
dc.contributor.authorTsilidis, Konstantinos K.en_US
dc.contributor.authorTravis, Ruth C.en_US
dc.contributor.authorGerke, Travisen_US
dc.contributor.authorAlbanes, Demetriusen_US
dc.contributor.authorMucci, Lorelei A.en_US
dc.contributor.authorGiovannucci, Edwarden_US
dc.contributor.authorKraft, Peteren_US
dc.date.accessioned2015-07-01T20:56:51Z
dc.date.available2016-07-05T17:27:58Zen
dc.date.issued2015-06-15en_US
dc.identifier.citationShui, Irene M.; Mondul, Alison M.; Lindström, Sara ; Tsilidis, Konstantinos K.; Travis, Ruth C.; Gerke, Travis; Albanes, Demetrius; Mucci, Lorelei A.; Giovannucci, Edward; Kraft, Peter (2015). "Circulating vitamin D, vitamin Dâ related genetic variation, and risk of fatal prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium." Cancer 121(12): 1949-1956.en_US
dc.identifier.issn0008-543Xen_US
dc.identifier.issn1097-0142en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/111998
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.othercirculating 25‐hydroxyvitamin Den_US
dc.subject.otherfatal prostate canceren_US
dc.subject.othergene‐environment interactionen_US
dc.subject.othersingle‐nucleotide polymorphismsen_US
dc.subject.othervitamin D genesen_US
dc.titleCirculating vitamin D, vitamin D–related genetic variation, and risk of fatal prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortiumen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbsecondlevelPublic Healthen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/111998/1/cncr29320.pdf
dc.identifier.doi10.1002/cncr.29320en_US
dc.identifier.sourceCanceren_US
dc.identifier.citedreferenceLin X, Lee S, Christiani DC, Lin X. Test for interactions between a genetic marker set and environment in generalized linear models. Biostatistics. 2013; 14: 667 ‐ 681.en_US
dc.identifier.citedreferenceFang F, Kasperzyk JL, Shui I, et al. Prediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer. PLoS One. 2011; 6: e18625.en_US
dc.identifier.citedreferenceTretli S, Hernes E, Berg JP, Hestvik UE, Robsahm TE. Association between serum 25(OH)D and death from prostate cancer. Br J Cancer. 2009; 100: 450 ‐ 454.en_US
dc.identifier.citedreferenceHolt SK, Kolb S, Fu R, Horst R, Feng Z, Stanford JL. Circulating levels of 25‐hydroxyvitamin D and prostate cancer prognosis. Cancer Epidemiol. 2013; 37: 666 ‐ 670.en_US
dc.identifier.citedreferenceYin M, Wei S, Wei Q. Vitamin D receptor genetic polymorphisms and prostate cancer risk: a meta‐analysis of 36 published studies. Int J Clin Exp Med. 2009; 2: 159 ‐ 175.en_US
dc.identifier.citedreferenceAhn J, Albanes D, Berndt SI, et al. Vitamin D–related genes, serum vitamin D concentrations and prostate cancer risk. Carcinogenesis. 2009; 30: 769 ‐ 776.en_US
dc.identifier.citedreferenceHolt SK, Kwon EM, Peters U, Ostrander EA, Stanford JL. Vitamin D pathway gene variants and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2009; 18: 1929 ‐ 1933.en_US
dc.identifier.citedreferenceHolick CN, Stanford JL, Kwon EM, Ostrander EA, Nejentsev S, Peters U. Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. Cancer Epidemiol Biomarkers Prev. 2007; 16: 1990 ‐ 1999.en_US
dc.identifier.citedreferenceMondul AM, Shui IM, Yu K, et al. Genetic variation in the vitamin D pathway in relation to risk of prostate cancer—results from the Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2013; 22: 688 ‐ 696.en_US
dc.identifier.citedreferenceHolt SK, Kwon EM, Koopmeiners JS, et al. Vitamin D pathway gene variants and prostate cancer prognosis. Prostate. 2010; 70: 1448 ‐ 1460.en_US
dc.identifier.citedreferenceSchumacher FR, Berndt SI, Siddiq A, et al. Genome‐wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet. 2011; 20: 3867 ‐ 3875.en_US
dc.identifier.citedreferenceLi H, Stampfer MJ, Hollis JB, et al. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med. 2007; 4: e103.en_US
dc.identifier.citedreferenceInternational HapMap Consortium, Frazer KA, Ballinger DG, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature. 2007; 449: 851 ‐ 861.en_US
dc.identifier.citedreferenceRosner B, Cook N, Portman R, Daniels S, Falkner B. Determination of blood pressure percentiles in normal‐weight children: some methodological issues. Am J Epidemiol. 2008; 167: 653 ‐ 666.en_US
dc.identifier.citedreferenceWu MC, Kraft P, Epstein MP, et al. Powerful SNP‐set analysis for case‐control genome‐wide association studies. Am J Hum Genet. 2010; 86: 929 ‐ 942.en_US
dc.identifier.citedreferenceLiu D, Ghosh D, Lin X. Estimation and testing for the effect of a genetic pathway on a disease outcome using logistic kernel machine regression via logistic mixed models. BMC Bioinformatics. 2008; 9: 292.en_US
dc.identifier.citedreferenceLin X, Cai T, Wu MC, et al. Kernel machine SNP‐set analysis for censored survival outcomes in genome‐wide association studies. Genet Epidemiol. 2011; 35: 620 ‐ 631.en_US
dc.identifier.citedreferenceGao X. Multiple testing corrections for imputed SNPs. Genet Epidemiol. 2011; 35: 154 ‐ 158.en_US
dc.identifier.citedreferenceKristal AR, Till C, Song X, et al. Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev. 2014; 23: 1494 ‐ 1504.en_US
dc.identifier.citedreferenceHofmann JN, Yu K, Horst RL, Hayes RB, Purdue MP. Long‐term variation in serum 25‐hydroxyvitamin D concentration among participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev. 2010; 19: 927 ‐ 931.en_US
dc.identifier.citedreferenceWang TJ, Zhang F, Richards JB, et al. Common genetic determinants of vitamin D insufficiency: a genome‐wide association study. Lancet. 2010; 376: 180 ‐ 188.en_US
dc.identifier.citedreferenceTannour‐Louet M, Lewis SK, Louet JF, et al. Increased expression of CYP24A1 correlates with advanced stages of prostate cancer and can cause resistance to vitamin D3‐based therapies. FASEB J. 2014; 28: 364 ‐ 372.en_US
dc.identifier.citedreferenceMa J, Stampfer MJ, Gann PH, et al. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomarkers Prev. 1998; 7: 385 ‐ 390.en_US
dc.identifier.citedreferenceMikhak B, Hunter DJ, Spiegelman D, Platz EA, Hollis BW, Giovannucci E. Vitamin D receptor ( VDR ) gene polymorphisms and haplotypes, interactions with plasma 25‐hydroxyvitamin D and 1,25‐dihydroxyvitamin D, and prostate cancer risk. Prostate. 2007; 67: 911 ‐ 923.en_US
dc.identifier.citedreferenceJohn EM, Schwartz GG, Koo J, Van Den Berg D, Ingles SA. Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. Cancer Res. 2005; 65: 5470 ‐ 5479.en_US
dc.identifier.citedreferenceBodiwala D, Luscombe CJ, French ME, et al. Polymorphisms in the vitamin D receptor gene, ultraviolet radiation, and susceptibility to prostate cancer. Environ Mol Mutagen. 2004; 43: 121 ‐ 127.en_US
dc.identifier.citedreferenceLevin GP, Robinson‐Cohen C, de Boer IH, et al. Genetic variants and associations of 25‐hydroxyvitamin D concentrations with major clinical outcomes. JAMA. 2012; 308: 1898 ‐ 1905.en_US
dc.identifier.citedreferenceWagner D, Trudel D, Van der Kwast T, et al. Randomized clinical trial of vitamin D 3 doses on prostatic vitamin D metabolite levels and Ki67 labeling in prostate cancer patients. J Clin Endocrinol Metab. 2013; 98: 1498 ‐ 1507.en_US
dc.identifier.citedreferenceDeeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer. 2007; 7: 684 ‐ 700.en_US
dc.identifier.citedreferenceGiovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control. 2005; 16: 83 ‐ 95.en_US
dc.identifier.citedreferenceFeldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014; 14: 342 ‐ 357.en_US
dc.identifier.citedreferenceAhn J, Peters U, Albanes D, et al. Serum vitamin D concentration and prostate cancer risk: a nested case‐control study. J Natl Cancer Inst. 2008; 100: 796 ‐ 804.en_US
dc.identifier.citedreferenceHendrickson WK, Flavin R, Kasperzyk JL, et al. Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol. 2011; 29: 2378 ‐ 2385.en_US
dc.identifier.citedreferenceTravis RC, Crowe FL, Allen NE, et al. Serum vitamin D and risk of prostate cancer in a case‐control analysis nested within the European Prospective Investigation Into Cancer and Nutrition (EPIC). Am J Epidemiol. 2009; 169: 1223 ‐ 1232.en_US
dc.identifier.citedreferenceShui IM, Mucci LA, Kraft P, et al. Vitamin D–related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case‐control study. J Natl Cancer Inst. 2012; 104: 690 ‐ 699.en_US
dc.identifier.citedreferenceAlbanes D, Mondul AM, Yu K, et al. Serum 25‐hydroxy vitamin D and prostate cancer risk in a large nested case‐control study. Cancer Epidemiol Biomarkers Prev. 2011; 20: 1850 ‐ 1860.en_US
dc.identifier.citedreferenceGilbert R, Martin RM, Beynon R, et al. Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose‐response meta‐analysis. Cancer Causes Control. 2011; 22: 319 ‐ 340.en_US
dc.identifier.citedreferenceToriola AT, Nguyen N, Scheitler‐Ring K, Colditz GA. Circulating 25‐hydroxyvitamin D levels and prognosis among cancer patients: a systematic review. Cancer Epidemiol Biomarkers Prev. 2014; 23: 917 ‐ 933.en_US
dc.identifier.citedreferenceGiovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the Health Professionals Follow‐Up Study. Int J Cancer. 2007; 121: 1571 ‐ 1578.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr29320.pdf
Size:
168.3KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.